157 related articles for article (PubMed ID: 12792727)
41. Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme.
Stark AM; Hugo HH; Witzel P; Mihajlovic Z; Mehdorn HM
Zentralbl Neurochir; 2003; 64(1):30-6. PubMed ID: 12582944
[TBL] [Abstract][Full Text] [Related]
42. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
43. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
44. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
45. The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma.
Coupland SE; Anastassiou G; Stang A; Schilling H; Anagnostopoulos I; Bornfeld N; Stein H
J Pathol; 2000 Jun; 191(2):120-6. PubMed ID: 10861569
[TBL] [Abstract][Full Text] [Related]
46. Hepatocellular carcinoma--survival and clinical characteristics in relation to various histologic molecular markers in Western patients.
Schöniger-Hekele M; Hänel S; Wrba F; Müller C
Liver Int; 2005 Feb; 25(1):62-9. PubMed ID: 15698400
[TBL] [Abstract][Full Text] [Related]
47. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
[TBL] [Abstract][Full Text] [Related]
48. Head and neck inflammatory myofibroblastic tumor (IMT): evaluation of clinicopathologic and prognostic features.
Ong HS; Ji T; Zhang CP; Li J; Wang LZ; Li RR; Sun J; Ma CY
Oral Oncol; 2012 Feb; 48(2):141-8. PubMed ID: 22014665
[TBL] [Abstract][Full Text] [Related]
49. Mitotic count, nuclear atypia, and immunohistochemical determination of Ki-67, c-myc, p21-ras, c-erbB2, and p53 expression in granulosa cell tumors of the ovary: mitotic count and Ki-67 are indicators of poor prognosis.
King LA; Okagaki T; Gallup DG; Twiggs LB; Messing MJ; Carson LF
Gynecol Oncol; 1996 May; 61(2):227-32. PubMed ID: 8626138
[TBL] [Abstract][Full Text] [Related]
50. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
[TBL] [Abstract][Full Text] [Related]
51. Sclerosing poorly differentiated liposarcoma: clinicopathological, immunohistochemical and molecular analysis of a distinct morphological subtype of lipomatous tumour of soft tissue.
Suster S; Morrison C
Histopathology; 2008 Feb; 52(3):283-93. PubMed ID: 18269578
[TBL] [Abstract][Full Text] [Related]
52. Histopathological re-classification of extremity pleomorphic soft tissue sarcoma has clinical relevance.
Massi D; Beltrami G; Capanna R; Franchi A
Eur J Surg Oncol; 2004 Dec; 30(10):1131-6. PubMed ID: 15522563
[TBL] [Abstract][Full Text] [Related]
53. Fibrosarcoma versus fibromatoses and cellular nodular fasciitis. A comparative study of their proliferative activity using proliferating cell nuclear antigen, DNA flow cytometry, and p53.
Oshiro Y; Fukuda T; Tsuneyoshi M
Am J Surg Pathol; 1994 Jul; 18(7):712-9. PubMed ID: 7517104
[TBL] [Abstract][Full Text] [Related]
54. Extraskeletal osteosarcomas: a clinicopathologic study of 25 cases.
Lidang Jensen M; Schumacher B; Myhre Jensen O; Steen Nielsen O; Keller J
Am J Surg Pathol; 1998 May; 22(5):588-94. PubMed ID: 9591729
[TBL] [Abstract][Full Text] [Related]
55. Critical reappraisal of primary osseous composite sarcoma (malignant mesenchymoma) - analysis of four cases and literature review.
Chow LT
APMIS; 2016 Jun; 124(6):487-99. PubMed ID: 27102568
[TBL] [Abstract][Full Text] [Related]
56. "Malignant Mesenchymoma" Revisited: A Clinicopathologic Study of Leiomyosarcomas With Osteosarcomatous Differentiation.
Yu S; Hornick JL
Am J Surg Pathol; 2022 Oct; 46(10):1430-1435. PubMed ID: 35687345
[TBL] [Abstract][Full Text] [Related]
57. A study of proliferative markers and tumor suppressor gene proteins in different grades of ependymomas.
Sharma MC; Ghara N; Jain D; Sarkar C; Singh M; Mehta VS
Neuropathology; 2009 Apr; 29(2):148-55. PubMed ID: 18721229
[TBL] [Abstract][Full Text] [Related]
58. Primitive myxoid mesenchymal tumor of infancy: report of two cases and review of the literature.
Gong Q; Wang Z; Li X; Fan Q
Pathol Int; 2012 Aug; 62(8):549-53. PubMed ID: 22827764
[TBL] [Abstract][Full Text] [Related]
59. Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma.
Resetkova E; Gonzalez-Angulo AM; Sneige N; Mcdonnell TJ; Buzdar AU; Kau SW; Yamamura Y; Reuben JM; Hortobagyi GN; Cristofanilli M
Cancer; 2004 Sep; 101(5):913-7. PubMed ID: 15329897
[TBL] [Abstract][Full Text] [Related]
60. Malignant mesenchymoma of the orbit: case report and review of the literature.
Brannan PA; Schneider S; Grossniklaus HE; Mutema GK; Tarle I; Kersten RC; Kulwin DR
Ophthalmology; 2003 Feb; 110(2):314-7. PubMed ID: 12578773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
